Top

Published in:

01-08-2009 | Invited Commentary

Does hormonal therapy decrease tamoxifen associated hot flashes?

Authors: Debra L. Barton, Charles L. Loprinzi

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Excerpt

The manuscript by Osborne et al. [1] addresses the question of whether hormonal therapy will decrease hot flashes in patients receiving tamoxifen. Managing hot flushes is important as they are a very challenging side effect of tamoxifen which can negatively impact various areas of a woman’s life; including sleep and relationships. …

Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O’Shaughnessy JA (2009) The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-008-0284-y

Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C (2009) Efficacy of non-estrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause (in press)

Loprinzi C, Zahasky K, Sloan J, Novotny P, Quella S (2000) Tamoxifen-induced hot flashes. Clin Breast Cancer 1(1):52–56. doi:10.3816/CBC.2000.n.004 PubMedCrossRef

Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J (2006) Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 24(24):3991–3996. doi:10.1200/JCO.2005.04.3745 PubMedCrossRef

Loprinzi CL, Michalak JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE et al (1994) Megestrol acetate for the prevention of hot flashes. N Engl J Med 331(6):347–352. doi:10.1056/NEJM199408113310602 PubMedCrossRef

Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR et al (2006) Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north central cancer treatment group trial N99C7. J Clin Oncol 24(9):1409–1414. doi:10.1200/JCO.2005.04.7324 PubMedCrossRef

Title: Does hormonal therapy decrease tamoxifen associated hot flashes?
Authors: Debra L. Barton
Charles L. Loprinzi
Publication date: 01-08-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0319-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2009

The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer

Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients

About the c.156_157insAlu BRCA2 breast cancer predisposing mutation

Identifying the “sentinel lymph nodes” for arm drainage as a strategy for minimizing the lymphedema risk after breast cancer therapy

Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas

A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer